Company / Gross Margin
Aclaris Therapeutics, Inc. Gross Margin History
FY2017-FY2018 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
52.7%
FY2018
5-year range
-
FY2017-FY2018
Trend
+283.8%
vs FY2017
Sector context
Sector data unavailable
Latest sector comparison
What the data says
52.7% in FY2018.
Gross Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2018, gross margin increased 283.8% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | 52.7% | +283.8% |
| FY2017 | 13.7% | - |
As of FY2018 · SEC 10-K · Updated Jun 24, 2026